依达拉奉联合参芎注射液对急性脑梗死患者C反应蛋白及白介素-17的影响  

Effects of edaravone combined with Shenxiong injection on plasma C-reactive protein and interleukin-17 in patients with acute cerebral infarction

作　　者：万玉杰[1] 曹修丽[2] 刘云海[1] 朱瑞云[1] 宋大庆[1] 

机构地区：[1]济宁市第一人民医院急诊内科,山东济宁2720002 [2]济宁市第一人民医院儿科

出　　处：《临床急诊杂志》2015年第12期941-943,946,共4页Journal of Clinical Emergency

摘　　要：目的:观察依达拉奉联合参芎注射液对急性脑梗死(ACI)患者血清C反应蛋白(CRP)及白介素-17(IL-17)的影响并评估疗效。方法:选择我院急诊内科住院ACI患者100例,并随机分为参芎组(对照组)和依达拉奉联合参芎组(观察组),每组备50例。均根据病情给予抗栓、脑细胞保护剂及适当降压、降血脂等常规治疗,对照组在常规治疗基础上给予注射用参芎葡萄糖注射液200 ml·d^(-1),静脉滴注,1次/d;观察组在参芎组治疗基础上加用依达拉奉注射液60 mg·d^(-1),分2次静脉滴注,2组疗程均为14 d。治疗前及治疗第5、14天时分别测定患者的血清CRP和血清IL-17浓度,并在第14天进行美国国立卫生研究院卒中量表(NIHSS)评分。结果:与治疗前比较,2组治疗第5、14天血清CRP和血清IL-17浓度均显著降低(P<0.05),且观察组血清CRP和IL-17浓度水平显著低于对照组(P<0.05)。第14天,2组NIHSS评分均显著降低(P<0.05),观察组NIHSS评分显著低于对照组(P<0.05),2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:参芎注射液、依达拉奉联合参芎注射液均能降低ACI患者血清CRP、IL-17浓度及NIHSS评分,联合应用降低更明显,对ACI患者的治疗更安全、有效。Objective：To observe the effects of edaravone combined with Shenxiong Injection on plasma C-reactive protein（CRP）and interleukin-17（IL-17）in patients with acute cerebral infarction.Method：One hundred cases of patients with acute cerebral infarction were randomly divided into control group and observation group with50 cases in each group.Based on conventional treatment of acute cerebral infarction,the control group was given Shenxiong.The observation group was treated with edaravone besides given above treatment.The therapeutic period was 14 days.The levels of CRP and IL-17 were detected before treatment and 5,14 dafter treatment.The NIHSS score were Compared before treatment and 14 day after treatment.Result：Compared with pretreatment,the levels of CRP and IL-17 in control group and observation group were significantly decreaed at 5,14 dafter treatment（P〈0.05）,and the CRP and IL-17 levels of observation group at 5,14 dof treatment were significantly lower than those of control group（all P〈0.05）.At 14 dafter treatment the NIHSS scores in control group and observation group were significantly decreaed（P〈0.05）.The NIHSS score of observation group at 14 dof treatment was significantly lower than that of control group（P〈0.05）.There were no significant difference betw-een 2groups in adverse reactions（P〉0.05）.Conclusion：Shenxiong and Edaravone Combined with Shenxiong can reduce the levels of CRP and IL-17 and fast the recovery of neural function.Combined treatment of the two drugs has a stronger effect and is safe and effective for patients with acute cerebral infarction.

关 键 词：急性脑梗死 依达拉奉 参芎注射液 C反应蛋白 白介素-17 

分 类 号：R743.33[医药卫生—神经病学与精神病学]